KPL-404
- Generic Name
- KPL-404
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 145
- Registration Number
- NCT05198310
- Locations
- 🇿🇦
Jacaranda Hospital, Pretoria, Gauteng, South Africa
🇿🇦Clinresco Centres (Pty) Ltd, Kempton Park, Gauteng, South Africa
🇿🇦Umhlanga Hospital Medical Center, Umhlanga, Kwazulu-Natal, South Africa
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Kiniksa Pharmaceuticals, Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT04497662
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Herston, Queensland, Australia
🇺🇸PPD Clinic, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath